MADRID (Reuters) - Spain’s Grifols has agreed to work with the U.S. Food and Drug Administration and other agencies to gather plasma from patients who have recovered from COVID-19 and test potential therapies for the disease, the pharmaceutical firm said on Wednesday.
The plasma will be processed to produce hyperimmune immunoglobins, which will then be put to pre-clinical and clinical tests to see if they can help treat the disease, Grifols said in a statement.
COVID-19 is caused by the coronavirus that is currently sweeping the globe.
Reporting by Isla Binnie; Editing by Chris Reese
Our Standards: The Thomson Reuters Trust Principles.